Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Lutetium Lu 177-DOTA-DUNP19 LNTH2403 · LNTH-2403

Radiopharmaceutical · Kills target cells, directed at leucine-rich repeat-containing protein 15 (LRRC15) · developed by Radiopharm Theranostics

Phase 1/2 Most advanced trial
RADX Developer
2 Registered trials

What is Lutetium Lu 177-DOTA-DUNP19 LNTH2403?

Lutetium Lu 177-DOTA-DUNP19 LNTH2403 is a lutetium-177 radiolabeled, humanized IgG1 monoclonal antibody that binds the external domain of LRRC15, which is expressed on certain tumor and stromal cells. After binding and internalization, it delivers beta radiation to LRRC15-expressing cells and can be visualized by SPECT/CT. It is being studied in colorectal cancer, head and neck squamous cell carcinoma, non-small cell lung cancer, triple negative breast cancer, and relapsed or refractory osteosarcoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
LNTH-2403
Drug type
Radiopharmaceutical
Targets
leucine-rich repeat-containing protein 15 (LRRC15)
Mechanism
Kills target cells, directed at leucine-rich repeat-containing protein 15 (LRRC15)
Pathways
TGF-beta signaling
Therapy area
Oncology
Developer
Radiopharm Theranostics, Ltd (RADX)
Also in trials of
LNTH
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07357519 Phase 1/2 Relapsed / Refractory Osteosarcoma Recruiting LNTH
NCT07272642 Phase 1 Imaging Not yet recruiting RADX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Colorectal CancerHead and Neck Squamous Cell CarcinomaImagingNon-Small Cell Lung CancerRelapsed / Refractory OsteosarcomaTriple Negative Breast Cancer (TNBC)

Other drugs acting on LRRC15

More from Radiopharm Theranostics

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the RADX page.

Follow RADX, the company behind Lutetium Lu 177-DOTA-DUNP19 LNTH2403

See RADX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

RADX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.